Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
USA118th CongressHR-6227| House
| Updated: 11/10/2023
David Schweikert
Republican Representative
Arizona
Cosponsors (35)
Doug LaMalfa (Republican)Diana Harshbarger (Republican)Michael C. Burgess (Republican)Ruben Gallego (Democratic)Raúl M. Grijalva (Democratic)Vince Fong (Republican)Keith Self (Republican)Stephanie I. Bice (Republican)Mariannette Miller-Meeks (Republican)Eric Swalwell (Democratic)Melanie A. Stansbury (Democratic)Scott H. Peters (Democratic)Andrea Salinas (Democratic)John Joyce (Republican)Kelly Armstrong (Republican)Brittany Pettersen (Democratic)Blake D. Moore (Republican)August Pfluger (Republican)Larry Bucshon (Republican)Jim Costa (Democratic)David G. Valadao (Republican)Michelle Steel (Republican)Debbie Lesko (Republican)Kevin McCarthy (Republican)Dan Crenshaw (Republican)Jay Obernolte (Republican)Juan Ciscomani (Republican)Monica De La Cruz (Republican)Lizzie Fletcher (Democratic)Yadira Caraveo (Democratic)Kevin Mullin (Democratic)Teresa Leger Fernandez (Democratic)Susie Lee (Democratic)Troy Balderson (Republican)Mike Levin (Democratic)
Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationHealth promotion and preventive carePrescription drugs
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
USA118th CongressHR-6227| House
| Updated: 11/10/2023
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
David Schweikert
Republican Representative
Arizona
Cosponsors (35)
Doug LaMalfa (Republican)Diana Harshbarger (Republican)Michael C. Burgess (Republican)Ruben Gallego (Democratic)Raúl M. Grijalva (Democratic)Vince Fong (Republican)Keith Self (Republican)Stephanie I. Bice (Republican)Mariannette Miller-Meeks (Republican)Eric Swalwell (Democratic)Melanie A. Stansbury (Democratic)Scott H. Peters (Democratic)Andrea Salinas (Democratic)John Joyce (Republican)Kelly Armstrong (Republican)Brittany Pettersen (Democratic)Blake D. Moore (Republican)August Pfluger (Republican)Larry Bucshon (Republican)Jim Costa (Democratic)David G. Valadao (Republican)Michelle Steel (Republican)Debbie Lesko (Republican)Kevin McCarthy (Republican)Dan Crenshaw (Republican)Jay Obernolte (Republican)Juan Ciscomani (Republican)Monica De La Cruz (Republican)Lizzie Fletcher (Democratic)Yadira Caraveo (Democratic)Kevin Mullin (Democratic)Teresa Leger Fernandez (Democratic)Susie Lee (Democratic)Troy Balderson (Republican)Mike Levin (Democratic)
Health Subcommittee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationHealth promotion and preventive carePrescription drugs